Merck Millipore Announces Exclusive Agreement with Julphar Diabetes
News Aug 08, 2012
Merck Millipore announced an exclusive agreement to sell recombinant human insulin manufactured by the United Arab Emirates-based pharmaceutical production company Julphar Diabetes. The insulin is of non-animal origin and will be marketed under Merck Millipore's CellPrime™ brand name, complementing the company's range of non-animal origin supplements for cell culture biomanufacturing.
CellPrime™ Insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines. It also effectively enhances cell growth rate and therapeutic protein production, while preventing morphological abnormalities of the cells.
"CellPrime™ Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety," said Burghard Freiberg, Senior Vice President Pharm Chemicals Solutions. "Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective."
Joe Saldanha, GM of Julphar Diabetes said, "This agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that the state of the art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such a strong partner in the Life Science sector.''
Julphar Diabetes is the division of Julphar that manages the manufacturing and commercialization of diabetes products. The Julphar Diabetes facility (Julphar XI) is built in accordance with the latest EMEA regulations, utilizing the best available technologies in the market to comply with the latest international quality standards.
Merck Millipore partnered with Julphar Diabetes as its source for recombinant human insulin as the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries. The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency.
Extra-Resistant Wheat is Created From New Gene CombinationNews
A new combination of different strains of resistant wheat may help farmers avoid a common fungal disease.READ MORE
Boyds Acquires New Cambridge Office to Support Rapid GrowthNews
Boyds, the drug development consultancy which helps pharmaceutical companies translate great science into marketable medicines for patient benefit, has relocated into new premises in Cambridge.READ MORE